- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Philips Set to Launch Enhanced Neurovascular Imaging System at ECR
Emphasizing upgraded angio suite capabilities as well as improved 2D and 3D imaging, Philips will unveil the Azurion Neuro Biplane System at the European Congress of Radiology.
In order to help enhance interventional workflows for neurovascular procedures, Philips is slated to debut the Azurion Neuro Biplane System at the European Congress of Radiology (ECR).
The Azurion Neuro Biplane System offers an integrated combination of 2D and 3D imaging with low-dose imaging capabilities to enhance stroke assessment and timely precision intervention in neurovascular procedures, according to Philips.
Designed to enhance interventional workflows for stroke assessment and neurovascular procedures, the Azurion Neuro Biplane System is slated to launch at the European Congress of Radiology (ECR). (Image courtesy of Philips.)
“Working closely with leading interventionists, we designed the latest Azurion neuro biplane (system) to meet their requirements of superior patient care, optimized angio suite performance, and efficient return on investment,” said Mark Stoffels, the business leader of image guided therapy systems at Philips. “Together, I am confident we can continue to reduce the impact of stroke, helping more patients to recover faster and reducing long-term impact on their health.”
The company noted that other key features with the Azurion Neuro Biplane System include automated beam rotation, improved C-arm rotation and X-ray detector positioning flexibility.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
